Used in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulated dopamine signaling. It modulates striatal signaling pathways by increasing cyclic adenosine monophosphate (cAMP) levels, which helps restore balance in neural circuits associated with cognition, motivation, and motor control. Due to its ability to cross the blood-brain barrier and exhibit favorable pharmacokinetic properties in preclinical models, it serves as a valuable tool compound in target validation and proof-of-concept studies for novel antipsychotic therapies.